Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INBX Inhibrx	$13.62 +5.1%	$12.37	$10.80 ▼ $18.95	$197.16M	N/A	117,490 shs	21,994 shs
INMB INmune Bio	$7.29 +1.4%	$7.50	$4.32 ▼ $10.50	$167.55M	1.63	266,850 shs	224,045 shs
PRQR ProQR Therapeutics	$1.78	$1.47	$1.07 ▼ $4.62	$187.28M	0.35	633,200 shs	142,743 shs
XLO Xilio Therapeutics	$0.67 -3.9%	$0.78	$0.62 ▼ $1.70	$34.84M	-0.27	1.42 million shs	2.09 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INBX Inhibrx	-4.42%	+0.78%	+6.67%	-4.64%	-20.25%
INMB INmune Bio	-3.62%	-1.51%	-7.35%	-11.23%	-23.92%
PRQR ProQR Therapeutics	+5.95%	+6.59%	-10.55%	-11.88%	-8.72%
XLO Xilio Therapeutics	-37.99%	-20.79%	-6.68%	-18.42%	-35.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INBX Inhibrx	2.3231 of 5 stars	0.0	1.0	4.6	3.8	2.5	1.3
INMB INmune Bio	1.8692 of 5 stars	3.6	0.0	0.0	2.7	1.7	0.6
PRQR ProQR Therapeutics	2.9543 of 5 stars	4.6	3.0	0.0	3.5	0.0	0.0
XLO Xilio Therapeutics	2.4101 of 5 stars	3.5	2.0	0.0	2.5	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INBX Inhibrx	2.00	Hold	N/A	N/A
INMB INmune Bio	3.17	Buy	$22.80	212.76% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	349.44% Upside
XLO Xilio Therapeutics	3.00	Buy	$4.00	494.53% Upside

Current Analyst Ratings Breakdown

Latest XLO, INBX, PRQR, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	INBX Inhibrx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/14/2025	PRQR ProQR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
3/14/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/10/2025	PRQR ProQR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INBX Inhibrx	$200K	985.82	N/A	N/A	N/A	∞
INMB INmune Bio	$50K	3,351.07	N/A	N/A	$2.07 per share	3.52
PRQR ProQR Therapeutics	$18.97M	9.87	N/A	N/A	$0.55 per share	3.24
XLO Xilio Therapeutics	$9.27M	3.76	N/A	N/A	$1.34 per share	0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INBX Inhibrx	-$154.96M	$116.75	0.12	N/A	N/A	N/A	-113.74%	-80.56%	6/16/2025 (Estimated)
INMB INmune Bio	-$30.01M	-$1.93	N/A	N/A	N/A	N/A	-117.48%	-78.96%	7/30/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.43M	-$0.35	N/A	N/A	N/A	-134.31%	-71.58%	-19.70%	8/7/2025 (Estimated)
XLO Xilio Therapeutics	-$76.40M	-$0.84	N/A	N/A	N/A	N/A	-211.50%	-80.31%	8/14/2025 (Estimated)

Latest XLO, INBX, PRQR, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/13/2025	Q1 2025	XLO Xilio Therapeutics	$0.10	-$0.18	-$0.28	-$0.18	$42.00 million	$2.93 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
3/27/2025	Q4 2024	INMB INmune Bio	-$0.54	-$0.40	+$0.14	-$0.40	N/A	N/A
3/17/2025	Q4 2024	INBX Inhibrx	-$2.88	-$3.09	-$0.21	-$3.09	N/A	$0.10 million
3/11/2025	Q4 2024	XLO Xilio Therapeutics	-$0.22	-$0.20	+$0.02	-$0.20	$2.26 million	$1.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INBX Inhibrx	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INBX Inhibrx	N/A	4.70	4.70
INMB INmune Bio	N/A	2.59	2.59
PRQR ProQR Therapeutics	N/A	2.33	2.33
XLO Xilio Therapeutics	N/A	1.67	1.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INBX Inhibrx	82.46%
INMB INmune Bio	12.72%
PRQR ProQR Therapeutics	32.65%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
INBX Inhibrx	17.09%
INMB INmune Bio	35.20%
PRQR ProQR Therapeutics	8.40%
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INBX Inhibrx	166	14.48 million	11.26 million	Optionable
INMB INmune Bio	10	22.98 million	14.37 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	74.82 million	Optionable
XLO Xilio Therapeutics	70	51.78 million	41.67 million	Not Optionable

XLO, INBX, PRQR, and INMB Headlines

Recent News About These Companies

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2 at 8:46 AM | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2 at 7:33 AM | stockhouse.com

Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants

June 2 at 6:33 AM | quiverquant.com

Xilio Therapeutics Announces Proposed Public Offering

June 2 at 6:11 AM | globenewswire.com

Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial

May 31 at 8:48 PM | insidermonkey.com

Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer

May 31 at 8:34 AM | quiverquant.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31 at 8:00 AM | globenewswire.com

Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest

May 30, 2025 | americanbankingnews.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finanznachrichten.de

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finance.yahoo.com

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2025 | globenewswire.com

Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year

March 11, 2025 | markets.businessinsider.com

Xilio Therapeutics files $250M mixed securities shelf

March 11, 2025 | markets.businessinsider.com

Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates

March 11, 2025 | zacks.com

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025 | globenewswire.com

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

February 24, 2025 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

February 12, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, INBX, PRQR, and INMB Company Descriptions

Inhibrx NASDAQ:INBX

$13.62 +0.66 (+5.09%)

As of 01:41 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

INmune Bio NASDAQ:INMB

$7.29 +0.10 (+1.39%)

As of 01:40 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

ProQR Therapeutics NASDAQ:PRQR

$1.78 0.00 (0.00%)

As of 01:47 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Xilio Therapeutics NASDAQ:XLO

$0.67 -0.03 (-3.90%)

As of 01:46 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time